Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Amortization of Deferred Charges of $900000.0 for Q1 2026, up 145.69% on a QoQ basis from -$2.0 million in Q4 2025, and up 12.5% year-over-year from $800000.0 in Q1 2025.
Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $900000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges rose 12.5% year-over-year to $900000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $530000.0 (down 83.47% YoY) and the FY2025 annual result came in at $537000.0, down 82.14% from the prior year.
- Amortization of Deferred Charges was $900000.0 for Q1 2026 at Xeris Biopharma Holdings, up from -$2.0 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $900000.0 in Q1 2026 and bottomed at -$2.0 million in Q4 2025.
- A 5-year average of $454235.3 and a median of $600000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Peak annual rise in Amortization of Deferred Charges reached 351.98% in 2025, while the deepest fall reached 344.11% in 2025.
- Xeris Biopharma Holdings' Amortization of Deferred Charges stood at $489000.0 in 2022, then increased by 2.25% to $500000.0 in 2023, then surged by 61.4% to $807000.0 in 2024, then sank by 344.11% to -$2.0 million in 2025, then surged by 145.69% to $900000.0 in 2026.
- Business Quant data shows XERS's Amortization of Deferred Charges at $900000.0 in Q1 2026, -$2.0 million in Q4 2025, and $800000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.41 Bn | 1.30 Bn | 72.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 900,000.00 |
| Mar 31, 2026 | 900,000.00 |
| Dec 31, 2025 | -1.97 Mn |
| Dec 31, 2025 | -1.97 Mn |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 807,000.00 |
| Dec 31, 2024 | 807,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Mar 31, 2024 | 177,000.00 |
| Mar 31, 2024 | 177,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |